[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359545-105":59,"doc-detail-359545-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-the-cox-2pge2-axis-to-enhance-nk-and-t-cell-immunotherapy-in-brain-tumors","Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors","","Aggressive brain tumors such as glioblastoma (GBM) remain among the most lethal cancers, with a median survival of about 15 months despite multimodal therapy. Resistance is shaped by the blood–brain barrier, intratumoral heterogeneity, and a profoundly immunosuppressive tumor microenvironment. NK and T cell immunotherapies offer breakthroughs but are constrained by chronic neuroinflammation, with PGE2 generated via the COX-2 pathway driving immune evasion and therapeutic resistance. The COX-2/PGE2 axis can impair cytotoxic immunity, promote CD8+ exhaustion and regulatory T cell expansion, and contribute to resistance against checkpoint inhibitors, CAR-T, and chemotherapy. Targeting this pathway, including PGE2 modulation with next-generation NK/T cell platforms such as CAR-NK, may restore immune function and improve outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-cox-2pge2-axis-to-enhance-nk-and-t-cell-immunotherapy-in-brain-tumors/359545/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-cox-2pge2-axis-to-enhance-nk-and-t-cell-immunotherapy-in-brain-tumors/359545.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are NK and T cell immunotherapies challenging in glioblastoma?","Question",{"text":112,"@type":113},"They can be limited by chronic neuroinflammation and an immunosuppressive tumor microenvironment that suppresses cytotoxic function.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the COX-2/PGE2 axis affect NK and T cell activity?",{"text":117,"@type":113},"PGE2 signals through EP2/EP4 to raise cAMP, impairing cytotoxic immunity, downregulating NK activating receptors, inducing CD8+ T cell exhaustion, and promoting regulatory T cell expansion.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategy does the document propose to improve treatment?",{"text":121,"@type":113},"Targeting the COX-2/PGE2 pathway to restore NK and T cell function and sensitize tumors to immunotherapy, potentially combined with CAR-NK or CAR-T approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359545,1790178086,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Immunology, Immunotherapy (2026) 75:141  \n[https://doi.org/10.1007/s00262-026-04372-5](https://doi.org/10.1007/s00262-026-04372-5)  \nTargeting the COX‑2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors  \nChih‑Jie Shen1 · Joy Florentino‑Krasnov2 · You‑Cheng Liao3 · Hong‑WenTang4 ·  \nBahagia Willibrordus Maria Nainggolan5 · Yung‑Hsiao Chiang1,3,6,7,8,9 · Tsung‑I. Hsu1,2,3,10,11,12  \nReceived: 29 December 2025 / Accepted: 18 March 2026 © The Author(s) 2026  \nAbstract  \nAggressive brain tumors such as glioblastoma (GBM) remain among the most lethal human cancers, with a median survival of only 15 months despite multimodal treatment. Their resistance arises from a triad of barriers—the blood–brain barrier (BBB), marked intratumoral heterogeneity, and a profoundly immunosuppressive tumor microenvironment (TME) . Immunotherapeutic strategies based on natural killer (NK) and T cells, leveraging antigen-independent cytotoxicity and antigen-specific precision, respectively, offer potential breakthroughs but are often limited by chronic neuroinflammation. A key driver ofTME suppression is prostaglandin E2 (PGE2), produced via the cyclooxygenase-2 (COX-2) pathway. PGE2 exerts a dual role: Intracellularly, it can promote apoptosis, whereas extracellularly, it fosters tumor progression, immune evasion, and therapeutic resistance. Through activation of EP2 and EP4 receptors, PGE2 signals via Gαs proteins to elevate cyclic adenosine monophosphate (cAMP), leading to impaired cytotoxic immunity. This signaling downregulates NK cell activating receptors (e.g. , NKG2D, NKp30), induces CD8⁺ T cell exhaustion, and promotes regulatory T cell expansion. The COX-2/PGE₂ axis further mediates resistance to checkpoint inhibitors, CAR-T therapy, and chemotherapy by enhancing neuronal excitation through EP1 receptor activation in GBM. Targeting this pathway has therefore emerged as a compelling therapeutic strategy, which can restore NK and T cell function and sensitize tumors to immunotherapy. Combining PGE₂ modulation with next-generation NK/T cell approaches—including CAR-NK and CAR-T platforms—holds promise to overcome immune resistance and redefine therapeutic paradigms for GBM and other central nervous system malignancies.  \n*  \n*  \n1  \n2  \n3  \n4  \n5  \n6  \nYung-Hsiao Chiang [ychiang@tmu.edu.tw](ychiang@tmu.edu.tw)  \n[Tsung-I. Hsu](Tsung-I. Hsu)  \n[dabiemhsu@tmu.edu.tw](dabiemhsu@tmu.edu.tw)  \nTMU Research Center of Neuroscience, Taipei Medical University, Taipei 110, Taiwan  \nInternational Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan  \nPh.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan  \nProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore  \nDepartment of Neurosurgery, Universitas Sumatera Utara, Medan 20154, North Sumatera, Indonesia  \nDepartment of Neurosurgery, Taipei Medical University Hospital, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan  \n7 Department of Surgery, College of Medicine, Taipei Medical University, Taipei 110, Taiwan  \n8 Taipei Neuroscience Institute, Taipei Medical University, Taipei 110, Taiwan  \n9 Department of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan  \n10 TMU Research Center of Cancer Translational Medicine, Taipei 110, Taiwan  \n11 Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan  \n12 Ph.D. Program in Innovative Medical Technology Research and Development Industry, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan  \nGraphical Abstract  \nKeywords Glioblastoma · Prostaglandin E2 · NK and T cell immunotherapy · Tumor microenvironment · EP2/EP4 receptors  \nIntroduction  \nBrain tumors, particularly glioblast","cbCain0USDOkOuQW","https://ap.wps.com/l/cbCain0USDOkOuQW","pdf",1027831,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why are NK and T cell immunotherapies challenging in glioblastoma?\",\"answer\":\"They can be limited by chronic neuroinflammation and an immunosuppressive tumor microenvironment that suppresses cytotoxic function.\"},{\"question\":\"How does the COX-2/PGE2 axis affect NK and T cell activity?\",\"answer\":\"PGE2 signals through EP2/EP4 to raise cAMP, impairing cytotoxic immunity, downregulating NK activating receptors, inducing CD8+ T cell exhaustion, and promoting regulatory T cell expansion.\"},{\"question\":\"What therapeutic strategy does the document propose to improve treatment?\",\"answer\":\"Targeting the COX-2/PGE2 pathway to restore NK and T cell function and sensitize tumors to immunotherapy, potentially combined with CAR-NK or CAR-T approaches.\"}]","Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors | PDF",1790137145,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dee79c0a30426a61703f60327e6cdc4.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f1bb320c1a328ba1eb54abbe512edc2.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1cb6fb09dedb9b28cb1585b2a63099f.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30468ac01e57b7aa6fbeec2317a5afb8.webp",980,1301]